I'm sure it will get asked. It's the answer that's of greater concern. A so-called news release about clinical trials may have "popped" the stock with any wording of South Korea in it. The fact that it's not is a forecast the SK question will be like the space shuttle launch being cancelled yesterday - an expensive and time consuming dud. Mills have been spent on SK. Just straight up give us an update on that. That's what shareholders need.